ライフサイエンスコーパス: be calculated using

1 The all-cause mortality risk score was calculated using 0.0398 x (age) + 0.516 x (renal ins

2 NSES was calculated using 1990 US Census data (block groups;

3 Financial cost to the patient was calculated using 2 different methods (hospital billi

4 ht ventricular free wall longitudinal strain were calculated using 2-dimensional speckle-tracking ech

5 All costs were calculated using 2010 dollars.

6 Costs of care were calculated using 2015 US prices and the medication

7 A visual distortions index (%DI) was calculated using 3-dimensional threshold Amsler grid

8 were remeasured in 3 dimensions, and volumes were calculated using 3-dimensional software.

9 The FI was calculated using 50 preadmission frailty variables.

10 Risk scores are calculated using a cradle-to-gate LCA.

11 Each cost is calculated using a bottom-up approach where regional

12 ach and then, expected number of TR elements is calculated using a pair-Hidden Markov Models-based me

13 e accuracy of an inpatient diagnosis of MetS was calculated using a 1-month follow-up as the gold sta

14 The CMRglc of each brain region was calculated using a 3-compartment model and an operat

15 The CMRglc of each brain region was calculated using a 3-compartment model and an operat

16 The level of agreement for GFR determination was calculated using a Bland-Altman plot and Pearson cor

17 Relative survival was calculated using a conditional approach and expresse

18 ificity of the ROP diagnosis by experts that was calculated using a consensus reference standard diag

19 The effect of vWF on prognosis was calculated using a Cox regression model.

20 Incidence was calculated using a defined catchment population and

21 A third MR-AC was calculated using a model-based, postprocessing appro

22 The ctDNA fraction was calculated using a novel algorithm designed for the

23 of the binding between vancomycin and Zn(II) was calculated using a novel fluorometric assay, and NMR

24 ference between sides in individual patients was calculated using a paired difference t test and the

25 isoelectric point of each quantified protein was calculated using a set of 7 synthetic peptides spike

26 The dissociation constant (KD) was calculated using a two-site model of template affini

27 Kinetic parameters were calculated using a 1-tissue-compartment model and c

28 and mesio-lingual [ML]) and different PMPEs were calculated using a 15% cut-off point: 1) full-mouth

29 Odds ratios and 95% confidence intervals were calculated using a conditional logistic regression

30 OP, type 2 ROP, and ROP requiring treatment) were calculated using a consensus reference standard dia

31 Hazard ratios (HRs) were calculated using a Cox proportional hazard model, a

32 ratio (OR) estimates and associated 95% CIs were calculated using a fixed-effects model.

33 Misclassification rates were calculated using a Monte-Carlo 5-fold cross-validat

34 The sensitivity and specificity were calculated using a nested PCR as the gold standard

35 idated method and pharmacokinetic parameters were calculated using a non-compartmental model.

36 Tenofovir (TFV) pharmacokinetic parameters were calculated using a noncompartmental analysis.

37 Odds ratios were calculated using a random effect model.

38 Summary estimates were calculated using a random effects model.

39 Weighted mean differences in lipid levels were calculated using a random-effects model.

40 odds ratios (ORs) with corresponding 95% CIs were calculated using a random-effects model.

41 Hazard ratios were calculated using a time-dependent survival analysis

42 Driving times for 3.79x10(7) persons were calculated using a total of 3.88x10(7) available ro

43 The NEI-VFQ scores were calculated using a traditional subscale scoring alg

44 l odds ratios and causal hazard ratios (HRs) were calculated using a two-stage regression estimate wi

45 SUVRs were calculated using AAL (Automated Anatomical Labeling

46 A weighted index was calculated using adjusted hazard ratios for immunode

47 ed using the fibrosis 4 index (FIB-4), which is calculated using age, aminotransferases, and platelet

48 Patient Safety Indicators were calculated using Agency for Healthcare Research and

49 range of anti-JCV antibody index thresholds were calculated using all available data and applied to

50 Standardized mean differences (Hedges g) were calculated using all outcomes reported in the trial

51 ed enamel and dentin interface area (E%, D%) were calculated using Amira software.

52 d the elements Al, Ca, Fe, K, Na, Si, and Ti are calculated using an absolute minimum of sample prepa

53 ry steps in the various competing mechanisms are calculated using an ONIOM-based approach in which th

54 ed with moderate-to-severe periodontitis can be calculated using an evidence-based scoring index.

55 A time trend of CPPopt was calculated using an automated curve-fitting method t

56 Vascular density was calculated using an automated image thresholding met

57 Factor scores of clinical psychopathology were calculated using an item-wise confirmatory bifactor

58 ed coordinate- and image-based meta-analyses were calculated using anisotropic effect size signed dif

59 Good recoveries (98.8-103.3%) were calculated using anthocyanin-rich plant samples.

60 rations for the present and future scenarios were calculated using aviation emission inventories deve

61 Diagnostic accuracy versus FFR </=0.80 was calculated using binary cutoff values of </=0.90 for

62 End-systolic and end-diastolic volumes were calculated using blood pool images and applied to o

63 to the intention-to-treat principle, and CIs were calculated using bootstrap methods.

64 Patient complication risk was calculated using both the universal calculator and a

65 The MELD scores were calculated using both creatinine values and compare

66 The QALYs were calculated using Child Depression Rating Scale-Revi

67 Past innovation network structures are calculated using citation patterns across technology

68 Heat of hydrate dissociation was calculated using Clausius-Clapeyron equation and as

69 Recoveries were calculated using clean soils spiked with 100, 500,

70 tumors of the conjunctiva and eyelid margin were calculated using clinical examination with slitlamp

71 cific rates of adverse event free admissions were calculated using colorectal procedures as an exampl

72 Volume of the Schlemm canal was calculated using commercially available 3-dimensiona

73 Cumulative incidence rates were calculated using competing risk survival statistics

74 Cumulative incidence rates were calculated using competing risk survival statistics

75 ith caution due to high heterogeneity, which was calculated using comprehensive meta-analysis statist

76 An incidence rate ratio (IRR) was calculated using conditional Poisson regression, adj

77 Odds ratios and 95% confidence intervals were calculated using conditional logistic regression fo

78 atios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression mo

79 Odds ratios were calculated using conditional logistic regression mo

80 Risks were calculated using conditional logistic regression mo

81 risks (RR) and 95% confidence intervals (CI) were calculated using conditional logistic regression.

82 Incidence rate ratios were calculated using conditional logistic regression.

83 artiles of lipid-corrected metabolite levels were calculated using conditional logistic regression.

84 ORs were calculated using conditional logistic regression.

85 defined categories) of prediagnostic 25(OH)D were calculated using conditional logistic regression.

86 nce rate ratios and 95% confidence intervals were calculated using conditional logistic regression.

87 Odds ratios (OR) were calculated using conditional logistic regression.

88 Odds ratios were calculated using conditional logistic regressions a

89 er zoster relative to unexposed time periods were calculated using conditional Poisson regression.

90 a risk score, and risk of incident late AMD was calculated using Cox proportional hazard analysis.

91 -transformed IL-6, hsCRP, and D-dimer levels were calculated using Cox models.

92 Hazard ratios were calculated using Cox proportional hazard models in

93 sociated with the presence of BMPR2 mutation were calculated using Cox proportional hazards models st

94 tios (HR) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regressio

95 st cancer and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regressio

96 relative risks and 95% confidence intervals were calculated using Cox proportional hazards regressio

97 d hazard ratios (HRs) for retinal detachment were calculated using Cox proportional hazards regressio

98 Hazard ratios (HR) for mortality were calculated using Cox proportional hazards regressio

99 Hazard ratios (HRs) and 95% CIs were calculated using Cox proportional hazards regressio

100 expectancy and years of life saved after AMI were calculated using Cox proportional hazards regressio

101 otential treatment bias, hazard ratios (HRs) were calculated using Cox regression and were tested aga

102 thritis, and cancer) hazard ratios for death were calculated using Cox regression for 8,640 women and

103 s (HRs) of 42-day and one-year EVB mortality were calculated using Cox regression model.

104 ios (RRs) and 95% confidence intervals (CIs) were calculated using Cox regression, adjusting for know

105 ratio (HR) and 95% confidence interval (CI) were calculated using Cox's proportional hazards analysi

106 nd the reliability of the pass/fail decision were calculated using Cronbach alpha and Subkoviak metho

107 Adherence (< 4.5 years or >/= 4.5 years) was calculated using data from six monthly clinical visi

108 ombined PAR associated with the risk factors was calculated using data from the Health Survey for Eng

109 cortisol, major depression, and neuroticism were calculated using data from large genome wide associ

110 atment, on-treatment, and posttreatment care were calculated using data from Medicare reimbursement d

111 Result robustness was calculated using deterministic and probabilistic sen

112 eshes alongside their HOMO and LUMO orbitals were calculated using DFT calculations at the B3LYP/6-31

113 erization, of -116.0 and -144.4 kcal mol(-1) were calculated using DFT for the monomers of 3 and 4, r

114 PRSs were calculated using discovery effect size estimates we

115 Encapsulation efficiencies can be calculated using disk centrifuge photosedimentometry,

116 nd the left ventricular ROI, and mean counts were calculated using Elip-ROI and RG-ROI techniques.

117 The eGFR was calculated using equations from the CKD Epidemiology

118 The recurrence rate for each study was calculated using events/person years of follow-up (P

119 Absolute concentrations were calculated using extinction coefficients of each of

120 ence [MD] and relative risk/risk ratio [RR]) were calculated using fixed- and random-effects models.

121 al trajectories over time for ONH parameters were calculated using fractional polynomial modelling.

122 imorbidity in relation to sensitization ever were calculated using generalized estimating equations.

123 Adjusted prevalence ratios (aPRs) were calculated using generalized estimating equations.

124 IR and sensitivity were calculated using HOMA-IR and Matsuda indices.

125 -lamina cribrosa pressure difference (TLCPD) was calculated using ICP and IOP together with geometric

126 Maternal antibody half-life was calculated using infant antibody titers from birth t

127 Schizophrenia polygenic risk profile scores were calculated using information from the Psychiatric G

128 Revenue was calculated using insurance reimbursement data for va

129 Study-specific adjusted effect estimates were calculated using inverse probability of treatment-w

130 Cumulative survival free from an AE was calculated using Kaplan-Meier curves and Cox hazard

131 Cumulative survival free from adverse events was calculated using Kaplan-Meier curves and Cox proport

132 Cumulative stroke risk was calculated using Kaplan-Meier estimates.

133 The risk of relapse was calculated using Kaplan-Meier methods, and predictor

134 Corneal graft survival was calculated using Kaplan-Meier survival analysis, and

135 r recurrence, and melanoma-related mortality were calculated using Kaplan-Meier estimates, and Cox pr

136 idual cancer types, including breast cancer, were calculated using Kaplan-Meier estimates, Fine and G

137 Readmission rates and survival were calculated using Kaplan-Meier functions.

138 epression Scale Short Form, and trajectories were calculated using latent class growth curve analysis

139 f three (50-650 kW) run-of-river HP projects were calculated using life cycle assessment (LCA).

140 bond BDFE of Fe(II)-H2O (1) (68.6 kcal/mol) is calculated using linear fits to its Pourbaix diagram

141 Population estimates were calculated using linear interpolation from the 2000

142 -based heritability and genetic correlations were calculated using linkage disequilibrium score regre

143 program, and annual percent change in rates was calculated using log-linear regression.

144 Propensity score (PS) for insulin use was calculated using logistic regression including prede

145 Odds ratios and 95% confidence intervals were calculated using logistic regression analysis, adju

146 Odds ratios with 95% confidence intervals were calculated using logistic regression analysis.

147 ly Living (IADL<8) and cognitive performance were calculated using logistic regression analysis.

148 Odds ratios were calculated using logistic regression to account for

149 Odds ratios (ORs) were calculated using logistic regression, adjusting for

150 , and 45, other high-risk types, and any HPV were calculated using logistic regression.

151 Brain-predicted age was calculated using machine-learning analysis, trained

152 medians for estimated episode of care costs were calculated using marginal longitudinal two-part reg

153 acheobronchial and alveolar regions of lungs were calculated using measured 24-h UFP time series of s

154 The rate of PCT thinning was calculated using mixed effects models.

155 redicted readmission rates between hospitals was calculated using mixed-effects logistic regression a

156 tuberculin skin testing, and relative risks were calculated using modified Poisson regression models

157 and for CT of the chest, abdomen, and pelvis were calculated using Monte Carlo simulation studies.

158 ons from isobutanol by hydroxyl radical have been calculated using multi-path variational transition-

159 os (ORs) with 95% confidence intervals (CIs) were calculated using multivariable conditional logistic

160 Odds ratios were calculated using multivariable conditional logistic

161 Adjusted odds ratios were calculated using multivariable logistic regression.

162 justed risk ratios for preemptive transplant were calculated using multivariable-adjusted models and

163 e charges on the atoms and bond lengths have been calculated using natural bond orbital calculations,

164 Risk ratios (RRs) were calculated using negative binomial regression, cont

165 Organ and whole-body radiation exposures were calculated using OLINDA software.

166 nd radiation-absorbed doses to normal organs were calculated using OLINDA.

167 The ODs were calculated using OLINDA/EXM (version 1.0); EDs were

168 Absorbed doses were calculated using OLINDA/EXM 1.1.

169 oses to individual organs and the whole body were calculated using OLINDA/EXM 1.2 for the standard ma

170 Absorbed doses were calculated using OLINDA/EXM, version 1.1.

171 ean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.

172 Radiation dose estimates were calculated using OLINDA/EXM.

173 tor [TNF]-alpha) between baseline and week 8 were calculated using paired t test.

174 ity of TFS at 3 years given survival to S2P) was calculated using parametric conditional survival ana

175 Volumes were calculated using passive sampling theory and were b

176 Complications were calculated using patient safety indicators and Inte

177 Cerebral oxygen delivery was calculated using phase contrast angiography and pre-

178 These distributions were calculated using physiological NAD(+)/NADH ratios r

179 ive risks and 95% confidence intervals (CIs) were calculated using Poisson regression adjusted for ag

180 Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk

181 ted risk ratios for asthma at ages 5-9 years were calculated using Poisson regression models and pool

182 ks (RRs) with 95% confidence intervals (CIs) were calculated using Poisson regression, adjusted for a

183 Trends in standardized incidence were calculated using Poisson regression.

184 ates (illnesses per sample) by treatment arm were calculated using Poisson regression.

185 Incidence rate ratios were calculated using Poisson regressions while adjustin

186 ), and the degree of polarization uniformity was calculated using polarization-sensitive optical cohe

187 events in blacks and 1660 events in whites) were calculated using pooled Mantel-Haenszel estimates w

188 Oscillatory frequency and power were calculated using power spectral density analysis of

189 similar to pack-years of cigarette smoking), were calculated using predicted BMIs.

190 The local conduction velocity at each point was calculated using previously established methods.

191 ible indispensable amino acid scores (DIAAS) was calculated using published data on amino acids' dige

192 OptiVol fluid index was calculated using published methods.

193 The predicted cyto- and genotoxicity of DBPs was calculated using published potencies based on the co

194 Prevalence of early and late AMD was calculated using random-effects meta-analysis strati

195 orrelations between cortisol levels and HCVs were calculated using random effects.

196 Pooled standardized mean differences (SMDs) were calculated using random-effect models.

197 onal risk allele for each lipid pathway gene were calculated using random-effects inverse-weighted me

198 and during and after the first year of ART, were calculated using random-effects meta-analyses.

199 5% confidence interval (CI) of each variable were calculated using random-effects meta-analysis.

200 Summary statistics, risk ratios, and CIs were calculated using random-effects modeling.

201 Pooled estimates of incidence and mortality were calculated using random-effects models.

202 Summary relative risks were calculated using random-effects models.

203 xtapapillary choroidal volumetric parameters were calculated using raw thickness measurements and sta

204 D of the in vitro model was calculated using Re, the pressure gradient, Swamee-J

205 Thresholds for outcome prediction were calculated using receiver operating curves.

206 m homes with cats or dogs from those without were calculated using receiver-operating characteristics

207 cidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared wit

208 of exhaled nitric oxide, and medication use were calculated using regression models.

209 Changes in KCCQ scores were calculated using repeated measures analysis of cova

210 raction and Synthesis: Hedges g effect sizes were calculated using sample sizes, P values, and/or Coh

211 Phylogenetic community structure metrics were calculated using species pools that differed in spa

212 All shieldings are calculated using state-optimized pi-space complete-a

213 disease prevalence and treatment eligibility were calculated using stochastic simulation and populati

214 Multiple diffusion measures were calculated using streamline tractography, and corre

215 s for the development of Alzheimer's disease were calculated using summary statistics from the larges

216 compositions of such unusual "N5S2 moieties" were calculated using Suwannee River fulvic acid (SRFA)

217 ceived >/=14 days before delivery; trimester was calculated using Tdap date, infant's date of birth,

218 ier relaxation times for electrons and holes are calculated using the Bardeen and Shockley's deformat

219 Expansive growth rates are calculated using the calculated Pi values and are co

220 constant and the respective half-life could be calculated using the radioactive decay equations base

221 nce of samples (RGB-resolved absorbance) can be calculated using the RGB color values of only three p

222 TER are computed based on the SE of MER that is calculated using the bootstrap method.

223 A genomic matrix is calculated using the information from those markers o

224 ge-standardized prevalence of retinal emboli was calculated using the 2010 Singapore adult population

225 Dead space ventilation was calculated using the Bohr equation.

226 y determining the confidence interval, which was calculated using the bootstrap re-sampling technique

227 Estimated GFR (eGFR) was calculated using the Chronic Kidney Disease Epidemio

228 e position of CS domain in the pre-H/ACA RNP was calculated using the CSP data.

229 SNR was calculated using the formula: SNR=signal intensity (

230 The 5-year SCD risk was calculated using the HCM Risk-SCD formula.

231 Market competition was calculated using the Herfindahl Hirschman Index.

232 Agreement between the 2 methods was calculated using the intraclass correlation coeffici

233 Survival was calculated using the Kaplan-Meier method, and indepe

234 years of follow-up; postrecurrence survival was calculated using the Kaplan-Meier method.

235 DFS was calculated using the Kaplan-Meier method.

236 Overall survival was calculated using the Kaplan-Meier method.

237 e-free survival (DFS) for ymrEMVI and ypEMVI was calculated using the Kaplan-Meier product limit and

238 The primary endpoint was calculated using the least squares mean at each time

239 oped during the first 12 months of follow-up was calculated using the life-table method and was compa

240 The mean effective dose was calculated using the male and female models for the

241 Odds ratio (OR) was calculated using the Mantel-Haenszel method.

242 Accuracy was calculated using the mean absolute percentage error,

243 Glomerular filtration rate was calculated using the modification of diet in renal d

244 Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal D

245 PHA was calculated using the non-laboratory Framingham CVD r

246 dministered to children younger than 5 years was calculated using the NYC immunization information sy

247 Dosimetry was calculated using the OLINDA/EXM software.

248 Dry deposition of GOM at two sites was calculated using the passive sampler data and a mult

249 Ten-year predicted ASCVD risk was calculated using the pooled cohort risk equations.

250 REE solubility was calculated using the previously developed MSE (Mixed

251 corresponding intraocular lens power, which was calculated using the Sanders-Retzlaff-Kraff/Theoreti

252 BPND was calculated using the simplified reference tissue mod

253 For each protocol, a complexity score was calculated using the variables predicting warfarin d

254 Lung Injury Prediction Score was calculated using the worst values within the 12 hour

255 rom consecutive patients at an eye institute were calculated using the 5 formulas and super formula.

256 whole brain, ventricle, and midbrain volumes were calculated using the boundary-shift integral and at

257 BPND and SUVR were calculated using the cerebellar cortex as a referen

258 P values were calculated using the chi(2) test.

259 lectronic medical records, and complications were calculated using the Clavien-Dindo classification.

260 stance use disorders, and tobacco dependence were calculated using the Composite International Diagno

261 ios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox hazards model.

262 vitreal injections relative to those without were calculated using the Cox proportional hazard model.

263 ction (defined as eGFR <90 mL/min/1.73 m(2)) were calculated using the Cox proportional hazards model

264 ULN values were calculated using the cutoff levels suggested by the

265 Effective dose of Pu were calculated using the data of Pu: (130 +/- 21) nBq/m

266 Thirty-day risk-standardized mortality rates were calculated using the Hospital Compare statistical m

267 Particle mass emissions were calculated using the integrated particle size distr

268 Expected operative mortality rates were calculated using the International Registry of Acut

269 probabilities with 95% confidence intervals were calculated using the Kaplan-Meier estimator stratif

270 Time-to-event analyses were calculated using the Kaplan-Meier method with log-r

271 Survival estimates were calculated using the Kaplan-Meier method, and multi

272 mulative rates of melanoma-related mortality were calculated using the Kaplan-Meier method.

273 Survival rates were calculated using the Kaplan-Meier method.

274 Recurrence-free survivals (RFS) were calculated using the Kaplan-Meier method.

275 The corresponding theoretical spectra were calculated using the lowest energy conformation of

276 HIV genetic distances were calculated using the polymerase region.

277 Absolute risks of infection were calculated using the profile likelihood random-effe

278 Generated weighted means and 99% CIs were calculated using the reported means (SDs or SEs).

279 National estimates were calculated using the sampling weights of the NIS.

280 als of NPY2 receptors toward the radioligand were calculated using the simplified reference tissue me

281 Nondisplaceable binding potentials (BPNDs) were calculated using the simplified reference tissue mo

282 PTF and TBF were calculated using the standard single-tissue-compart

283 er-arm circumference, and head circumference were calculated using the WHO 2006 growth standards.

284 he lattice parameters of the solid solutions were calculated using their XRD patterns.

285 erate relative density and fractal dimension were calculated using these data and used to follow the

286 entropy and melting temperature of aluminum were calculated using this machine learning potential.

287 sotropy, axial, radial, and mean diffusivity were calculated using tract-based spatial statistics (TB

288 ignal of global and contralateral hemisphere was calculated using TSA.

289 s in the (31)PMRS spectrum, intracellular pH was calculated using two equations.

290 Annual hospital volume was calculated using unique hospital identifiers.

291 Annual operator and institutional volumes were calculated using unique identification numbers and

292 Cox proportional hazard ratios were calculated using univariate and multivariate models

293 and positive and negative predictive values were calculated using urine culture as the gold standard

294 ce of blindness within 10 years of diagnosis was calculated using US Census data.

295 The values are calculated using UV/visible near infrared spectra us

296 Clinic expenditures were calculated using vaccine price and administrative f

297 g observed-to-expected mortality ratios that were calculated using validated indexes for recipient an

298 Atrophy progression was calculated using voxel-based morphometry longitudina

299 Trends were calculated using weighted loglinear regression, and

300 Patient-specific tract maps were calculated using whole-brain analysis.